Identification of F5 as a Prognostic Biomarker in Patients with Gastric Cancer
Table 3
Stratified analysis of F5 genes and OS in GC patients.
Group
Low
High
Crude HR (95% CI)
Crude value
Adjusted HR (95% CI)
Adjusted valuea
Age (years)
<60
53
55
1.315 (0.68, 2.545)
0.416
1.878 (0.883, 3.994)
0.102
≥60
121
119
1.459 (0.996, 2.136)
0.052
1.446 (0.949, 2.202)
0.086
Pathological T
T 1/2
52
39
1.332 (0.632, 2.805)
0.451
1.164 (0.483, 2.806)
0.735
T 3/4
120
136
1.39 (0.96, 2.01)
0.81
1.56 (1.043, 2.334)
0.03
Pathological M
M0
11
13
0.418 (0.128, 1.37)
0.15
13.597 (1.012, 182.75)
0.049
M1
159
153
1.373 (0.965, 1.953)
0.078
1.357 (0.925, 1.991)
0.119
TNM stage
Stage I
28
19
1.726 (0.51, 5.839)
0.38
7.483 (0.732, 76.529)
0.09
Stage II
59
50
1.28 (0.652, 2.513)
0.474
1.235 (0.625, 2.438)
0.544
Stage III
68
79
1.439 (0.891, 2.324)
0.137
1.318 (0.798, 2.177)
0.281
Stage IV
14
21
1.852 (0.71, 4.83)
0.207
3.856 (1.135, 13.101)
0.031
Radiation therapy
Yes
30
32
3.389 (1.207, 9.522)
0.021
4.607 (1.323, 16.035)
0.016
No
137
129
1.282 (0.89, 1.847)
0.182
1.345 (0.913, 1.981)
0.133
Targeted molecular therapy
Yes
85
66
1.558 (0.919, 2.641)
0.099
1.885 (1.065, 3.338)
0.03
No
82
93
1.3 (0.829, 2.04)
0.254
1.35 (0.839, 2.17)
0.216
Cancer status
No
108
98
2.515 (1.25, 5.061)
0.01
2.852 (1.327, 6.127)
0.007
Yes
54
64
1.366 (0.884, 2.112)
0.161
1.277 (0.801, 2.037)
0.304
aAdjusted for age, TNM stage, radiation therapy, and targeted molecular therapy; the missing patients of these clinical parameters are the same as Table 1. Abbreviations: F5—Coagulation factor V; HR—hazard ratio; OS—overall survival; GC—gastric cancer.
